olmesartan has been researched along with Abdominal Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeva, AA | 1 |
| Azushima, K; Kanaoka, T; Kobayashi, R; Maeda, A; Matsuda, M; Ohki, K; Ohsawa, M; Tamura, K; Tokita, Y; Tsurumi-Ikeya, Y; Umemura, S; Uneda, K; Wakui, H; Yamashita, A | 1 |
2 other study(ies) available for olmesartan and Abdominal Obesity
| Article | Year |
|---|---|
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Imidazoles; Immune System Diseases; Inflammation; Interleukin-4; Lipid Metabolism; Nicotinamide Phosphoribosyltransferase; Obesity, Abdominal; Tetrazoles | 2013 |
Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders.
Topics: Adipocytes; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Gene Expression Regulation; Humans; Hypertrophy; Imidazoles; Interleukin-6; Metabolic Diseases; Mice; Obesity, Abdominal; Tetrazoles | 2014 |